Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo doubles down on next-gen weight loss therapy despite early setback
Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...
Novo Nordisk next-gen shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...
BioPharma Dive7d
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
pharmaphorum4d
Novo Nordisk’s oral amycretin tops Wegovy in obesity trial
The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...
Novo Nordisk stock surges 7% after Ozempic maker’s latest weight-loss drug shows promise
The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...
Business Wire29d
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies
Developing a broad portfolio of oral and injectable treatments Verdiva acquired ... once-weekly oral amylin agonist for use as monotherapy or in combination with an oral GLP-1 agonist A long ...